Eden vs Peter MD
Two GLP-1 desks, one scoreboard. We put Eden and Peter MD head-to-head on the published Brief Score — the same six factors, scored the same way.
The verdict
Eden takes this head-to-head.
Eden scores 91 to 76 on our six-factor Brief Score — A polished, high-disclosure program with strong nationwide coverage — you pay more, but you know exactly what you're paying for.
That doesn't make Peter MD a bad call — it's best for readers who want glp-1 care bundled with trt, sermorelin, nad+ or hair-loss treatment on a single account, and are comfortable reading a tiered price ladder rather than one flat monthly figure this site can map straight onto a dose. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Eden | Peter MD | |
|---|---|---|
| Brief Score | 91/100 (A−) | 76/100 (C) |
| Semaglutide | $239/mo | $149/mo new-user tier · $139/mo returning-user tier (GLP1 + B12) |
| Tirzepatide | $349/mo | $249/mo after a $149 first month (billed quarterly, 60mg) |
| Coverage | All 50 states | Most states — exclusions vary by treatment (not a single list) |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
Eden: Premium line steady; high supply-chain disclosure keeps our confidence high.
Peter MD: First reading, 2026-08-04: tirzepatide runs $149 the first month before resetting to $249 on quarterly billing; compounded semaglutide (sold as GLP1 + B12) splits into a $149/mo new-user tier and a $139/mo returning-user tier rather than one flat monthly rate.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.